Salix Pharmaceuticals Ltd (SLXP)
Quote as of 4:00 PM ET 09/02/2010 (NASDAQ GS)
| Last: 39.63 |
Change: $0.53 |
Percent Change: 1.36 |
Volume: 556,062 |
Salix Pharmaceuticals, Ltd. (Salix) is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are affecting the digestive tract. The Company?s products include XIFAXAN, MOVIPREP, OSMOPREP, VISICOL, APRISO, METOZOLV, AZASAN, ANUSOL-HC, PROCTOCORT cream, PEPCID, Oral Suspension DIURIL and COLAZAL. The Company?s products under development include Rifaximin, Crofelemer, Balsalazide disodium tablet and Budesonide foam.
Latest News
2:15:00 PM 8/30/2010
Salix Pharmaceuticals Announces Settlement of Pending Litigation Regarding MOVIPREP(R)
RALEIGH, N.C., Aug 30, 2010 (BUSINESS WIRE) --
Salix Pharmaceuticals, Ltd. (SLXP) today announced that Salix and
Norgine B. V. have entered into an agreement with Novel Laboratories,
Inc. to settle patent litigation currently pending in the U.S. District
Court for the District of New Jersey (Civil Action No. 3:08-02311
(FLW)(TJB)) regarding Novel's proposed generic version of MOVIPREP(R).
4:50:49 AM 8/10/2010
Revenue for Salix jumps 80 percent
Aug 10, 2010 (The News and Observer - McClatchy-Tribune Information Services via COMTEX) --
Salix Pharmaceuticals reported promising news about a potential new market for its top-selling drug Xifaxan, whose surging sales pushed the company's second-quarter revenue up 80 percent.
9:58:00 AM 8/9/2010
Salix Announces FDA Acceptance for Filing and Priority Review Designation For XIFAXAN550 sNDA For the Treatment of Non-Constipation Irritable Bowel Syndrome
RALEIGH, N.C., Aug 09, 2010 (BUSINESS WIRE) --
Salix Pharmaceuticals, Ltd. (SLXP) today announced the U.S. Food
and Drug Administration (FDA) has accepted for Priority Review the
Company's efficacy supplement to the New Drug Application (NDA) for
XIFAXAN(R) (rifaximin) 550 mg tablets for the proposed
indication of treatment of non-constipation irritable bowel syndrome
(Non-C IBS) and IBS-related bloating. Non-constipation irritable bowel
syndrome (Non-C IBS) encompasses two of the most common IBS subtypes:
patients with diarrhea-predominant symptoms (IBS-D) and patients who
suffer from intermittent periods of diarrhea and constipation known as
mixed IBS (IBS-M).
7:00:01 AM 7/29/2010
Salix Pharmaceuticals to Present at BMO Capital Markets Conference
RALEIGH, N.C., Jul 29, 2010 (BUSINESS WIRE) --
Salix Pharmaceuticals, Ltd. (SLXP) today announced that the
Company will present at the BMO Capital Markets 10th Annual
Focus on Healthcare Conference in New York, NY on Thursday, August 5 at
1:15 p.m. ET.